Assessment of venous thromboembolic disease (VTE) in oncology and haematology patients who presented to the Launceston General Hospital for treatment of their malignant disorder

Not Applicable

Completed

• Conditions: venous thromboembolic disease; Malignant disorder; Blood - Haematological diseases; Cancer - Any cancer

• Registration Number: ACTRN12611000762954
• Lead Sponsor: Clifford Craig Medical Trust Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-07-21
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 766

Inclusion Criteria

patients with hematological and malignant disorder who are over 18 years and presented with thromboembolic event to the Launceston General Hospital during the study period.

Exclusion Criteria

patients below 18 years of age and who may present outside the study period range.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess the prevalence of venous thromboembolism (VTE) among oncology and haematology patients who are treated at the Launceston General Hospital[12 months];To document the treatment modalities or any other related data such as coagulation profile for these patients in order to correlate this with the outcome.[12 months]

Secondary Outcome Measures

Name	Time	Method
To determine the risk factors for venous thromboembolism (VTE) in these patients.[12 months]